#121 - Azra Raza, M.D.: Why we're losing the war on cancer

Episode Summary

Executive Summary: Peter Attia interviews oncologist-researcher Azra Raza about her book The First Cell and her critique of modern cancer research. Raza argues that oncology has made limited progress in metastatic disease, relies on outdated models and expensive marginal therapies, and should shift far more resources toward prevention and early detection using human-based biomarkers and continuous monitoring.

Main Topics: Why Raza wrote The First Cell: Raza explains that decades of clinical care, lab research, widowhood from cancer, and the helplessness she felt treating a young man with glioblastoma compelled her to write the book and challenge the field. Oncology’s historical stagnation in advanced cancer: She argues that for most metastatic solid tumors, treatment still amounts to surgery, radiation, and chemotherapy, with survival gains often modest and not commensurate with decades of investment. The limits of current trial endpoints and drug approval: The discussion critiques reliance on partial response, progression-free survival, and cherry-picked trial populations, which can make small, expensive benefits look more meaningful than they are. Successes are real but narrow: Raza acknowledges major wins such as Gleevec in CML, ATRA/arsenic in APL, and some immunotherapy advances, but argues these successes apply to a small fraction of cancers and often to earlier, less malignant disease states. The failure of preclinical models: She contends that cell lines, mouse models, and other reductionist systems poorly represent human cancer, contributing to a very high failure rate when drugs reach patients. Cost, incentives, and financial toxicity: The conversation highlights how marginal survival gains can come with enormous prices, driving patient bankruptcy, distorted incentives, and a system optimized for approvals and revenue rather than outcomes. A proposed shift to early detection and prevention: Raza advocates reallocating resources toward biomarkers, liquid biopsies, continuous monitoring, and studying human tissue directly, arguing that catching cancer earlier is the only consistently successful strategy.

Key Arguments: Most progress in oncology has come from early detection and a few highly specific successes, not from broadly effective cures for metastatic disease. Age-adjusted cancer mortality has not meaningfully improved over the long term once smoking-related trends are accounted for. Clinical trial language such as partial response and progression-free survival can obscure the fact that many drugs extend life only by months, if at all. The current preclinical pipeline is deeply flawed because cell lines and animal models often do not reproduce human cancer biology. Drug development is misaligned with patient welfare because expensive therapies can produce tiny median survival gains while causing severe financial toxicity. The field should devote far more funding and intellectual effort to prevention, biomarker discovery, and early detection rather than continuing to overinvest in late-stage treatment paradigms. Immunotherapies and CAR-T are scientifically beautiful but still limited by toxicity, lack of tumor specificity, and narrow applicability. The most promising future lies in human-based longitudinal tissue repositories and multi-omic early-detection platforms rather than more of the same reductionist drug discovery. Academic and industry incentives, as well as publication and approval systems, encourage hype, overclaiming, and low-value research output. Cancer care should be judged by patient-centered outcomes and real survival benefit, not by regulatory or commercial success alone.

Data Points: Published manuscripts: Over 300 peer-reviewed manuscripts - Dr. Raza’s research output as described in the introduction Years in oncology: 30+ years - Raza describes decades of clinical oncology practice Patients seen weekly: 30 to 40 patients per week - Her long-running clinical workload Cancer mortality trend: Age-adjusted mortality in 2020 is the same as in 1930 - Raza’s argument that long-term progress has been far less than commonly believed Cancer mortality trend alternative: Same as 1970 over the last 50 years - Attia paraphrases the common framing; Raza says the longer view is even worse CML breakthrough: Gleevec approved in 2000 - Example of a major targeted therapy success Targeted therapy impact: Works for a very rare disease and a narrow biology - Raza argues Gleevec’s success does not generalize broadly Experimental agent failure rate: 95% - Raza says 95% of experimental cancer agents fail at the bedside Irreproducible papers: Up to 90% - Raza cites estimates that most high-profile science papers are not reproducible NCI funding: About $6 billion per year - Raza cites annual public cancer research funding Philanthropic funding: About $6 billion per year - Raza adds philanthropic cancer research funding to estimate total annual support Total research spending: Quarter of a trillion dollars - Raza’s estimate of cumulative cancer research investment AML treatment backbone: 7 and 3 regimen - She says the same AML backbone used in 1977 is still used in 2020 AML survival improvement: 10% to 26% five-year survival - Raza attributes the improvement largely to supportive care, not a new backbone regimen Cost of standard AML regimen: $5,000 - Approximate cost of the older 7+3 regimen per cycle Cost of liposomal/fancy AML version: $45,000 - Raza describes a newer approved formulation of the same drugs Survival gain for fancy AML version: 3.7 months median - Basis for approval in selected patients Financial toxicity: 42% - Raza says 42% of cancer patients are financially ruined by year two after diagnosis Breast cancer collections: 50% - She says half of breast cancer women are hounded by collection agencies with stage 4 disease Cancer cure fraction: 68% - Raza says 68% of newly diagnosed cancers are cured, largely with surgery/radiation/chemo and early detection Uncured advanced cases: 32% - Patients presenting with advanced disease where standard slash-poison-burn approaches are inadequate Phase one trial cost: $30 million - Estimated cost to take a candidate from preclinical work to first-in-human testing Drug approval cost: $2.5 billion - Estimated total cost to bring a drug to approval M-chip example: FDA-approved microfluidic PSA monitoring - Used to illustrate continuous biomarker monitoring from a drop of blood Cancer detection company example: 13 cancers in 4 hours for $180 - Raza cites Koshiba as an example of multi-cancer early detection Grail example: Phase 2 with almost 30 cancers - Raza cites Grail as another liquid biopsy/early detection company Omar’s cancer: Osteogenic sarcoma - A young man whose case illustrates the limits of treatment for aggressive solid tumors Andrew’s cancer: Glioblastoma multiforme, 9 cm tumor - A 22-year-old with catastrophic brain cancer that motivated Raza to write the book Harvey’s disease: Lymphoma with a 5-year battle - Raza’s husband and fellow oncologist, central to her personal perspective

Pivotal Quotes: "the only reason to write a book is if you absolutely can't not write it" — Peter Atiyah: Attia frames Raza’s motivation for writing as unavoidable and deeply compelled "I'm looking for an adult in the room" — Dr. Azra Raza: Her metaphor for the lack of sober, honest assessment in cancer research and treatment "the only successful strategy in cancer is early detection" — Dr. Azra Raza: Her central prescription for redirecting the field

Implications: The episode argues for a major reallocation of cancer research toward prevention, biomarkers, and early detection, while demanding more honest evaluation of drug value, trial endpoints, and costs. For patients, it underscores the importance of screening and skepticism toward hype.